DOACs have fewer drug interactions than warfarin Patients who switch from warfarin to DOACs have fewer potential drug interactions, an Australian study has found. A review of 712 patients with atrial fibrillation stopped warfarin to start apixaban or rivaroxaban found that the proportion of patients with no potential drug interactions increased from 47% to 63%. ...
News in brief: DOACs better for drug interactions; AML economic cost runs to billions; Blood disorder data unreliable
13 May 2021